Uses of the drug Actorisedron

Actorisedron is used to treat and prevent osteoporosis. Here is some helpful information about Actorisedron to help people learn to use it safely and effectively.

Actorisedron is a drug belonging to the group of analgesics, antipyretics, non-steroidal anti-inflammatory drugs, drugs for the treatment of Gout and joint diseases. Actorisedron is produced in the form of film-coated tablets and is packaged in a box of 1 blister of 2 tablets.
Actorisedron's main ingredient is Risedronate sodium 75mg and some other excipients, just enough for 1 tablet.

Actorisedron is used to treat patients in the following cases:
Actorisedron is used to treat and prevent osteoporosis in postmenopausal women. Prevention of fractures in postmenopausal women with osteoporosis. Actorisedron is used to treat osteoporosis in men.

Actorisedron is available as a film-coated tablet and is well tolerated by the oral route.
Actorisedron should be taken on an empty stomach, at least 30 minutes before breakfast, at least 2 hours from other meals or at least 30 minutes before bedtime.
Patients need to swallow the pill, remember not to break, suck or chew the tablet with a glass of plain water, keep an upright position for at least 30 minutes after taking it to help the medicine reach the stomach easily. Note that the patient should not lie down for 30 minutes after taking the medicine.

Dosage of Actorisedron drug depends on each subject and the course of the disease, there will be appropriate dosage. Below is the reference dose of Actorisedron as follows:
For adults: The recommended dose is 1 tablet of Actorisedron 35mg per week. Note that the patient takes the medicine on certain days of the week. In case the patient forgets to take a dose, it should be taken the next day after remembering, and then still take 1 Actorisedron tablet per week on the selected day. Do not take 2 tablets of 35mg Actorisedron in the same day. It is important for the patient to have a diet containing products containing calcium and vitamin D (eg, dairy products). Patients should supplement vitamin D and calcium if the diet is not adequate.

Severe overdose of Actorisedron after ingestion may lead to a decrease in serum calcium and phosphorus in some patients. There are also signs and symptoms of hypocalcemia in some other patients.
Treatment:
Patients should drink milk or antacids containing magnesium, calcium or aluminum to bind risedronate sodium and reduce drug absorption in the body. In case of serious overdose, the patient should be taken immediately to the nearest medical facility or hospital for timely treatment such as: Gastric lavage is required to remove the drug Actorisedron has not been absorbed or can be injected. Intravenous calcium to restore ionized calcium, alleviating signs or symptoms of hypocalcaemia.

Actorisedron should not be used in patients who are hypersensitive or have a history of allergy to Risedronate sodium or to any of its ingredients.
Do not use Actorisedron for patients with the following diseases:
Hypocalcemia (decreased calcium levels in the blood). Severe renal impairment (creatinine clearance < 30 ml/min). The patient is unable to stand or sit for at least 30 minutes. Actorisedron should not be used by pregnant or breastfeeding women, children, and adolescents.

Some interactions of the drug Actorisedron should be noted with the following drugs:
Using Actorisedron with drugs containing multivalent cations such as: Calcium, Magnesium, iron and aluminum. Because it can interfere with the absorption of Risedronate in the body. If it is necessary to take it, choose another time of day to take it, not at the same time as the Actorisedron drug. Consider carefully before using Actorisedron with estrogen supplements. Risedronate component in the drug is not metabolized in the body, does not induce the enzyme P450 and is less bound to proteins. Actorisedron should not be used with acetylsalicylic acid or NSAIDs. Because it can cause gastrointestinal side effects in patients.

During the use of Actorisedron, patients may experience some unwanted side effects such as:
Common:
Headache. Abdominal pain, indigestion, nausea, vomiting, diarrhea or constipation. Pain in bones, muscles and joints. Uncommon:
Gastritis, esophagitis, duodenitis, dysphagia. Inflammation of the eye. Disturbances in serum electrolytes such as hypocalcemia, hypophosphataemia. Rare:
Angioedema, pruritic rash. Glossitis, esophageal stricture. Leukopenia and liver enzyme disorders. Most of the above side effects of Actorisedron were mild to moderate in severity and did not usually require discontinuation of treatment.

It should be noted that Actorisedron should not be used together with food, drink and pharmaceutical products containing multivalent cations such as: Calcium, Magnesium, iron or aluminum because it may interfere with the absorption of Risedronate. use at the same time. Risedronate must be taken 30 minutes before eating, drinking or before taking another medicine for the first time of the day. Some osteoporosis drugs (Bisphosphonates), including Risedronate, can cause upper gastrointestinal disorders such as: Difficulty swallowing, esophagitis, gastritis, esophageal ulcer or peptic ulcer. Therefore, caution should be exercised when administering this drug to patients with the following medical conditions:
Patients with a history of esophageal disorders such as esophageal stricture or esophageal stricture that slow or make it difficult to pass food through the esophagus . The patient cannot hold an upright position for at least 30 minutes after taking Risedronate. Patients with upper gastrointestinal tract problems including Barrett's esophagus. Patients should pay close attention to the instructions for using Risedronate to minimize the risk of these side effects and warn patients to stop taking the drug, notify the doctor immediately if new or worsening symptoms appear. than.
Before using Risedronate to treat disease, patients need to thoroughly treat hypocalcaemia and disorders of bone and mineral metabolism such as: Parathyroid dysfunction, vitamin D deficiency. The addition of Calcium and Vitamin D is important for all patients, especially patients with Paget's disease of bone with significantly increased bone turnover.
Glucocorticoid-induced osteoporosis: Patients need to determine the status of sex steroid hormones of both men and women and consider appropriate replacement. Before using Actorisedron for the treatment and prevention of Glucocorticoid-induced osteoporosis. Osteonecrosis of the jaw: Cases of osteonecrosis of the jaw with use of the drug have also been reported in patients with osteoporosis taking bisphosphonates. For patients with factors such as cancer, chemotherapy, radiation therapy, corticosteroid use, poor oral hygiene. The need for a dental examination with appropriate dental prophylaxis should be considered prior to treatment with bisphosphonates in patients. During treatment with Bisphosphonates, patients should avoid invasive dental procedures such as extractions, dental implants. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may worsen the condition. In patients requiring dental procedures, discontinuation of bisphosphonate therapy may reduce the risk of osteonecrosis of the jaw. Bisphosphonate discontinuation should be considered by the treating physician or oral surgeon based on an individual patient's benefit and risk assessment. Atypical femoral fractures: Cases of long-term treatment of osteoporosis with bisphosphonates in patients with atypical femoral fractures have been reported. Therefore, patients on treatment with bisphosphonates should be counseled and monitored closely to report any thigh, hip or groin pain and any patient with such symptoms should be advised to seek medical attention. assessment of femur fractures. Patients suspected of having an atypical femoral fracture should be discontinued from bisphosphonate therapy for consideration based on an individual patient's risk and benefit assessment. Patients with renal impairment: The use of Actorisedron is not recommended in patients with severe renal impairment with creatinine clearance less than 30 ml/min. Actorisedron should not be used by women who are pregnant or breastfeeding. Before using the drug, it is necessary to consult a doctor. It should only be used when the potential benefit outweighs the possible risk to the fetus or nursing infant.